[go: up one dir, main page]

ATE259658T1 - Anästhetische zubereitung enthaltend einen nmda- antagonisten und einen alpha-2 adrenergen agonisten - Google Patents

Anästhetische zubereitung enthaltend einen nmda- antagonisten und einen alpha-2 adrenergen agonisten

Info

Publication number
ATE259658T1
ATE259658T1 AT00940519T AT00940519T ATE259658T1 AT E259658 T1 ATE259658 T1 AT E259658T1 AT 00940519 T AT00940519 T AT 00940519T AT 00940519 T AT00940519 T AT 00940519T AT E259658 T1 ATE259658 T1 AT E259658T1
Authority
AT
Austria
Prior art keywords
alpha
adrenergic agonist
nmda antagonist
anesthetical
preparation containing
Prior art date
Application number
AT00940519T
Other languages
English (en)
Inventor
Nicholas Franks
Mervyn Maze
Original Assignee
Protexeon Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10855216&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE259658(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Protexeon Ltd filed Critical Protexeon Ltd
Application granted granted Critical
Publication of ATE259658T1 publication Critical patent/ATE259658T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Anesthesiology (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AT00940519T 1999-06-11 2000-06-09 Anästhetische zubereitung enthaltend einen nmda- antagonisten und einen alpha-2 adrenergen agonisten ATE259658T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9913677.2A GB9913677D0 (en) 1999-06-11 1999-06-11 Formulation
PCT/GB2000/002271 WO2000076545A1 (en) 1999-06-11 2000-06-09 Anaesthetic formulation comprising an nmda-antagonist and an alpha-2 adrenergic agonist

Publications (1)

Publication Number Publication Date
ATE259658T1 true ATE259658T1 (de) 2004-03-15

Family

ID=10855216

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00940519T ATE259658T1 (de) 1999-06-11 2000-06-09 Anästhetische zubereitung enthaltend einen nmda- antagonisten und einen alpha-2 adrenergen agonisten

Country Status (14)

Country Link
US (1) US6562855B1 (de)
EP (1) EP1187635B1 (de)
JP (1) JP2003529541A (de)
AT (1) ATE259658T1 (de)
AU (1) AU778671B2 (de)
CA (1) CA2376916C (de)
DE (1) DE60008374T2 (de)
DK (1) DK1187635T3 (de)
ES (1) ES2215678T3 (de)
GB (2) GB9913677D0 (de)
PT (1) PT1187635E (de)
RU (1) RU2244558C2 (de)
WO (1) WO2000076545A1 (de)
ZA (1) ZA200110116B (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2812545B1 (fr) * 2000-08-03 2003-03-28 Air Liquide Sante Int Aerosol medicamenteux inhalable dans le traitement ou la prevention de la douceur
GB0209998D0 (en) * 2002-05-01 2002-06-12 Protexeon Ltd Use
CN1668315A (zh) 2002-06-12 2005-09-14 梅瑟·格里斯海姆有限公司 使用含氙气体进行脑保护
US20050255169A1 (en) * 2002-07-05 2005-11-17 Messer Griesheim Adjuvant containing xenon
WO2004052337A2 (de) * 2002-12-06 2004-06-24 Michael Georgieff Nasale pharmazeutische präparation enthaltend eine lipophile flüssige oder gasförmige wirksubstanz
AU2004283448B2 (en) * 2003-10-21 2009-02-19 Imperial Innovations Limited Use of xenon for the prevention of programmed cell death
US7795263B2 (en) * 2008-07-08 2010-09-14 Wildlife Laboratories, Inc. Pharmaceutical combination for and method of anesthetizing and immobilizing non-domesticated mammals
US20100022574A1 (en) * 2008-07-28 2010-01-28 EndogenX, Inc. Methods to Treat Pain Using an Alpha-2 Adrenergic Agonist and an Endothelin Antagonist
US8080550B2 (en) 2008-08-01 2011-12-20 Alpha Synergy Development, Inc. Anesthetic compositions and methods of use
US20110244058A1 (en) * 2008-08-01 2011-10-06 Gerald Horn Compositions and methods for treatment of pulmonary diseases and conditions
US20100203165A1 (en) 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of disorders or conditions of the eye
US12246013B2 (en) 2008-08-01 2025-03-11 Eye Therapies Llc Vasoconstriction compositions and methods of use
US8952011B2 (en) 2008-08-01 2015-02-10 Eye Therapies Llc Compositions and methods for the treatment of nasal conditions
RU2572692C2 (ru) * 2009-05-15 2016-01-20 Рекро Фарма, Инк. Сублингвальные композиции дексмедетомидина и способы их применения
US8987270B2 (en) 2009-07-27 2015-03-24 Eye Therapies Llc Formulations of selective alpha-2 agonists and methods of use thereof
US20110152271A1 (en) * 2009-12-17 2011-06-23 Gerald Horn Compositions and methods for ophthalmic delivery of nasal decongestants
AU2011204315A1 (en) * 2010-01-08 2012-08-02 Recro Pharma, Inc. Topical transdermal dexmedetomidine compositions and methods of use thereof
CN103068394A (zh) * 2010-04-15 2013-04-24 皇家学习促进学会/麦吉尔大学 对于疼痛的局部治疗
US8445526B2 (en) 2011-02-03 2013-05-21 Glaucoma & Nasal Therapies Llc Compositions and methods for treatment of glaucoma
US20130096170A1 (en) 2011-10-14 2013-04-18 Hospira, Inc. Methods of treating pediatric patients using dexmedetomidine
PE20142314A1 (es) 2011-12-11 2015-01-23 Recro Pharma Inc Composiciones intranasales de dexmedetomidina y metodos de uso de ellas
CN110464709A (zh) 2012-08-10 2019-11-19 德克萨斯州大学系统董事会 用于治疗中风的神经保护性脂质体组合物和方法
CA2905155C (en) 2013-03-15 2021-11-16 The Board Of Regents Of The University Of Texas System Liquids rich in noble gas and methods of their preparation and use
US8999938B2 (en) 2013-06-21 2015-04-07 Gnt Llc Ophthalmic lipophilic drug delivery vehicle formulations
CA2924233C (en) 2013-10-07 2018-10-23 Teikoku Pharma Usa, Inc. Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions
RU2648449C2 (ru) 2013-10-07 2018-03-26 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Способы и композиции для трансдермальной доставки неседативного количества дексмедетомидина
TWI704933B (zh) 2013-10-07 2020-09-21 美商帝國製藥美國股份有限公司 右美托咪啶經皮輸送裝置及使用其之方法
RU2557882C1 (ru) * 2014-07-08 2015-07-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Астраханская государственная медицинская академия" Министерства здравоохранения Российской Федерации (ГБОУ ВПО АГМА Минздрава России) Способ проведения премедикации при плановом хирургическом лечении
WO2017139382A1 (en) * 2016-02-08 2017-08-17 The Texas A&M University System Combination of adjuvant drugs esketamine and brimonidine for medical treatments

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4859685A (en) * 1986-08-13 1989-08-22 Boc, Inc. Anesthetic composition and method of using the same
US5605911A (en) * 1995-01-31 1997-02-25 Washington University Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH)
WO1997018317A1 (fr) 1995-11-13 1997-05-22 Commissariat A L'energie Atomique Complexe proteique dodecaedrique adenoviral, composition le contenant et ses applications
DE19709704C2 (de) 1997-03-10 1999-11-04 Michael Georgieff Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie
FR2787713A1 (fr) 1998-12-23 2000-06-30 Johan Huysman Composition en tant que medicament et utilisation d'une telle composition pour l'obtention d'un medicament destine a l'anesthesie, notamment medicament analgesique
DE19910986C2 (de) 1999-03-11 2001-06-07 Aga Ab Verwendung von Xenon bei der Behandlung von Neurointoxikationen
GB9917822D0 (en) * 1999-07-29 1999-09-29 Imperial College Nmda antagonist

Also Published As

Publication number Publication date
AU5544400A (en) 2001-01-02
ES2215678T3 (es) 2004-10-16
GB2352633B (en) 2002-04-17
JP2003529541A (ja) 2003-10-07
CA2376916C (en) 2010-09-21
WO2000076545A1 (en) 2000-12-21
CA2376916A1 (en) 2000-12-21
DK1187635T3 (da) 2004-06-21
EP1187635A1 (de) 2002-03-20
DE60008374D1 (de) 2004-03-25
GB2352633A (en) 2001-02-07
EP1187635B1 (de) 2004-02-18
PT1187635E (pt) 2004-07-30
ZA200110116B (en) 2003-07-23
AU778671B2 (en) 2004-12-16
GB0014165D0 (en) 2000-08-02
US6562855B1 (en) 2003-05-13
GB9913677D0 (en) 1999-08-11
DE60008374T2 (de) 2004-12-09
RU2244558C2 (ru) 2005-01-20

Similar Documents

Publication Publication Date Title
ATE259658T1 (de) Anästhetische zubereitung enthaltend einen nmda- antagonisten und einen alpha-2 adrenergen agonisten
MY129356A (en) Electrospun pharmaceutical compositions
EP1762236A3 (de) Formulierungen von alpha-adrenergen Rezeptor-Antagonisten und ihre Anwendungen
NO20024309D0 (no) Intradermal penetreringsmidler for topikal lokal anestetisk administrering
DK1169024T3 (da) Prægelatineret stivelse i en formulering med kontrolleret frigivelse
DE69808130D1 (de) Adamantan-derivate
GB2365772A (en) Factor
TW200505406A (en) Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
ATE345112T1 (de) Opioid enthaltende arzneiform gegen missbrauch
GEP20053568B (en) NMDA Receptor Agonist Pharmaceutical Compositions
HK1045113A1 (zh) 給予固定的曲馬朵和雙氯酚酸組合的口服給藥形式
ES2190205T3 (es) Combinacion para el tratamiento de la dependencia del alcohol que contiene un antagonista opioide y un modulador del complejo receptor de nmda.
SE0102843L (sv) Stabiliserad oral farmaceutisk komposition innehållande jodid och jodat och metod
IL159217A0 (en) An oral pharmaceutical formulation comprising a basic pharmaceutically active ingredient having ph-dependent solubility, a process for the manufacture thereof and use thereof in medicine
ATE287264T1 (de) Oral anzuwendende buprenorphinhaltige arzneimittel
IL141236A0 (en) New oral formulations for 5-ht4 agonists or antagonists
DE60102590D1 (de) Darreichungsformen zur behandlung von oralen mykosen
HUP0300419A3 (en) Estrogen agonist/antagonist metabolites, pharmaceutical compositions containing them and their use
WO2002015933A3 (en) Combination comprising an at1-receptor antagonist and an insulin secretion enhancer or an insulin sensitiser
DE50005082D1 (de) Verfahren zu Herstellung von PULVERFÖRMIGEn SOLUBILISATIONSHILFSSTOFFEn FÜR FESTE PHARMAZEUTISCHE DARREICHUNGSFORMEN
NO20010537L (no) Farmasøytiske preparater omfattende ibuprofen og domperidon
DE60006788D1 (de) Iod-herstellungszusammensetzung
MY130445A (en) Novel formulations of alpha-2, 4-disulfophenyl-n-tert-butylnitrone
ATE401084T1 (de) Torasemid enthaltende lagerstabile pharmazeutische zubereitungen
ATE297760T1 (de) Pharmazeutische zusammensetzungen enthaltend terbinafin

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1187635

Country of ref document: EP